Trial Profile
Phase II Study of Pembrolizumab (MK-3475) in Combination With Standard Therapy for Newly Diagnosed Glioblastoma
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Temozolomide (Primary)
- Indications Astrocytoma; Glioblastoma; Gliosarcoma
- Focus Adverse reactions; Therapeutic Use
- 29 Sep 2023 Planned End Date changed from 31 Aug 2023 to 31 Aug 2024.
- 29 Sep 2023 Planned primary completion date changed from 16 Aug 2023 to 31 Aug 2024.
- 14 Jun 2023 Status changed from recruiting to suspended.